Photochemotherapy Induces Interferon Type III Expression via STING Pathway.

Area of Science:

• Immunology
• Oncology
• Dermatology

Background:

• DNA-damaging cancer therapies can stimulate immune responses, enhancing treatment efficacy.
• The Stimulator of Interferon Genes (STING) pathway is crucial for detecting cytoplasmic DNA and activating immune signaling.
• Cutaneous T-cell lymphoma (CTCL) is a type of skin cancer affecting T-cells.

Purpose of the Study:

• To investigate the immune-activating effects of 8-methoxypsoralen plus UVA light (8-MOP + UVA) on CTCL cells.
• To elucidate the role of the STING pathway in the response of CTCL cells to photochemotherapy.

Main Methods:

• Treatment of CTCL cells with 8-MOP + UVA.
• Analysis of interferon expression, focusing on type III interferon (IFNL1).
• Assessment of STING and cyclic GMP-AMP synthase (cGAS) pathway involvement.
• Gene expression profiling to identify activated immune pathways.

Main Results:

• 8-MOP + UVA treatment induced significant interferon expression in CTCL cells, with IFNL1 being the major induced cytokine.
• IFNL1 upregulation was dependent on the STING and cGAS pathways.
• Photochemotherapy activated innate immune and inflammatory response pathways, including those related to tumor necrosis factor.
• A subset of these activated genes was found to be regulated by the STING-IFNL1 pathway.

Conclusions:

• The study establishes a link between DNA damage induced by 8-MOP + UVA and immune system activation via the STING pathway in CTCL.
• This research provides insights into the mechanisms underlying the effectiveness of photochemotherapy in treating CTCL.
• The findings highlight the potential of targeting the STING-IFNL1 pathway to enhance cancer immunotherapy.